[Paradigm change in the assessment of myeloid and lymphoid neoplasms associated with occupational benzene exposure]. / Paradigmenwechsel in der Beurteilung myeloischer und lymphatischer Neoplasien bei beruflicher Benzolexposition (BK-Ziffer 1303).

Benzene-caused hematologic neoplasms may be recognized as an occupational disease (OD) according to the German ordinance on ODs. At present, the OD No. 1303 covers heterogeneous diseases and various chemical agents triggering these diseases. The members of the medical advisory board specializing in ODs within the Ministry of Employment and Social Affairs recently proposed excluding "diseases of the blood, the hematopoietic and lymphatic system caused by benzene" from OD No. 1303 and classifying them as a separate OD. Benzene is generally acknowledged as a cause of acute myeloid leukemia, proven by numerous epidemiologic studies. However, there is less epidemiologic evidence of its association with other hematologic neoplasms, notably non-Hodgkin's lymphoma (NHL). To clarify this issue, the experts evaluated international literature and concluded that all kinds of myeloid and lymphoid malignancies including their prestages can be caused by occupational benzene exposure. Hence, physicians should ask patients about occupational benzene exposure and report any kind of diagnosed hematologic neoplasms, including their prestages, as suspected OD. The advisory board considered that a dose range starting from 10 ppm-years (cumulative benzene exposure) is sufficient for a > 50% probability of causing leukemias according to the WHO classification, including chronic lymphatic leukemia, and the potential preleukemias aplastic anemia and myelodysplastic syndrome, but excluding chronic myeloid leukemia (CML). For NHL and myeloproliferative diseases (including CML) the present epidemiologic evidence is considered not to be sufficient to describe a precise dose-effect relationship.

[Practice of recognizing benzene-caused occupational diseases in 2006]. / Beurteilung myeloischer und lymphatischer Neoplasien bei beruflicher Benzolexposition. Anerkennungspraxis benzolbedingter Erkrankungen im Jahr 2006.

BACKGROUND AND PURPOSE: Benzene-caused hematologic diseases can be recognized as occupational diseases (ODs) if they fulfill the legal requirements specified under No. 1303 of the appendix of the German ordinance on ODs. The aim of this study is to analyze the most important criteria that determined whether these diseases were recognized or rejected as ODs according to No. 1303 in 2006. METHODS: In 2006, 70 suspected cases of OD No. 1303 reported in North Rhine-Westphalia were examined in terms of diagnosis, notifiers, cumulative benzene exposures, professions, coexposures, delays in notification, latency periods, interim periods, and recognition criteria. RESULTS: 70 benign and malignant diseases of myeloid and lymphoid origin were reported as suspected ODs, among them 41 B-cell non-Hodgkin's lymphomas (B-cell NHL). Latency periods ranged between 14 and 57 years (median 37; mean 36.3+/-11.4; n=45), estimated cumulative benzene exposures varied from 0 to 144 ppm-years (median 12; mean 11.4+/-22.8; n=59). Four of 70 suspected cases were recognized as OD No. 1303. In 37 cases (52.9%), the nature of the disease was assessed as being nontypical of OD No. 1303, in 50 cases (71.4%), no sufficient benzene exposure could be found. Mature-cell NHL and Hodgkin's lymphoma were not recognized as OD. Cumulative benzene exposures